International Journal of Inflammation, Cancer and Integrative Therapy
Open Access

Diabetic nephropathy (DN) is one of the leading causes of chronic kidney disease (CKD) and end-stage renal disease (ESRD) globally. It represents a serious complication of both type 1 and type 2 diabetes, characterized by progressive kidney damage that can ultimately lead to renal failure. Despite advances in the management of diabetes and its complications, diabetic nephropathy continues to be a major cause of morbidity and mortality. One of the key factors driving the progression of DN is microinflammation, a low-grade, chronic inflammation that is often present even before clinical symptoms of nephropathy appear.

Microinflammation plays a pivotal role in the pathogenesis of DN, contributing to kidney injury, fibrosis, and the deterioration of kidney function. The activation of various inflammatory pathways in response to hyperglycemia, oxidative stress, and metabolic abnormalities can exacerbate the kidney’s vulnerability to damage. Recent studies have focused on understanding the molecular mechanisms behind microinflammation in DN, which could lead to novel therapeutic approaches aimed at mitigating or even reversing kidney damage. This article explores the mechanisms underlying microinflammation in diabetic nephropathy and examines the current and emerging therapeutic implications for treating this debilitating condition [1].

Description

The mechanisms of microinflammation in diabetic nephropathy

Microinflammation in diabetic nephropathy is characterized by the activation of both the innate and adaptive immune systems, leading to the release of pro-inflammatory cytokines, chemokines, and other mediators that contribute to tissue injury and fibrosis in the kidney. Several mechanisms are implicated in the initiation and perpetuation of microinflammation in DN, including hyperglycemia, oxidative stress, endothelial dysfunction, and the activation of immune cells such as macrophages and T lymphocytes.

Hyperglycemia and the formation of advanced glycation end products (AGEs): One of the central features of diabetes is chronic hyperglycemia, which directly contributes to the development of diabetic nephropathy. Elevated blood glucose levels lead to the formation of advanced glycation end products (AGEs), which are harmful compounds formed when glucose reacts with proteins, lipids, or nucleic acids. AGEs accumulate in various tissues, including the kidneys, and bind to specific receptors called RAGE (Receptor for AGEs). The binding of AGEs to RAGE on endothelial cells, mesangial cells, and other kidney cells activates pro-inflammatory signaling pathways, such as the nuclear factor-kappa B (NF-κB) pathway. This activation results in the production of cytokines like TNF-α (tumor necrosis factor-alpha), IL-1β (interleukin-1 beta), and IL-6 (interleukin-6), which promote inflammation and fibrosis in the kidneys [2].

Oxidative stress and mitochondrial dysfunction: Oxidative stress is another critical factor in the development of microinflammation in diabetic nephropathy. In a hyperglycemic environment, the overproduction of reactive oxygen species (ROS) leads to cellular damage, inflammation, and activation of the immune system. ROS damage cellular structures, including lipids, proteins, and DNA, leading to mitochondrial dysfunction and further ROS generation, creating a vicious cycle of oxidative stress. In the kidneys, this oxidative damage promotes inflammation by activating pro-inflammatory pathways such as the NF-κB pathway and the NLRP3 (NOD-like receptor family, pyrin domain containing 3) inflammasome, which contributes to the release of cytokines and the recruitment of immune cells to the site of injury [3].

Endothelial dysfunction and the activation of immune cells: Hyperglycemia and oxidative stress also lead to endothelial dysfunction, characterized by reduced nitric oxide (NO) availability and increased vascular permeability. This dysfunction promotes the activation of endothelial cells, which express adhesion molecules such as ICAM-1 (intercellular adhesion molecule-1) and VCAM-1 (vascular cell adhesion molecule-1). These adhesion molecules facilitate the recruitment of immune cells, including monocytes and T lymphocytes, to the kidneys. Once in the kidneys, these immune cells release pro-inflammatory cytokines and further contribute to the inflammatory environment that drives kidney damage. Macrophages, in particular, play a key role in the progression of diabetic nephropathy by secreting cytokines and growth factors that promote fibrosis and tubular atrophy.

Inflammasome activation and fibrosis: The NLRP3 inflammasome, a multiprotein complex involved in the activation of caspase-1 and the secretion of pro-inflammatory cytokines such as IL-1β and IL-18, has been implicated in the pathogenesis of diabetic nephropathy. The activation of the NLRP3 inflammasome in response to hyperglycemia, ROS, and other metabolic disturbances contributes to kidney inflammation and fibrosis. Fibrosis, the accumulation of excess extracellular matrix components like collagen, leads to the progressive scarring and stiffening of kidney tissue, impairing kidney function and contributing to the decline in glomerular filtration rate (GFR). The activation of the inflammasome and subsequent release of inflammatory mediators also drive the recruitment and activation of fibroblasts, which promote the deposition of fibrous tissue in the kidneys [4].

The role of the renin-angiotensin-aldosterone system (RAAS): The renin-angiotensin-aldosterone system (RAAS) is another key regulator of microinflammation in diabetic nephropathy. In diabetes, the activation of RAAS is enhanced by hyperglycemia and increased oxidative stress. Angiotensin II, a key effector of RAAS, promotes inflammation by stimulating the production of pro-inflammatory cytokines and growth factors. Angiotensin II also activates immune cells such as macrophages and T lymphocytes, contributing to the inflammatory milieu in the kidneys. Additionally, aldosterone, another key component of RAAS, has been shown to exacerbate fibrosis by promoting the activation of fibroblasts and the deposition of collagen.

Therapeutic implications

Given the central role of microinflammation in the progression of diabetic nephropathy, targeting inflammatory pathways offers a promising strategy for treating or preventing this debilitating condition. Several therapeutic approaches, both pharmacological and non-pharmacological, have been proposed to address the underlying inflammation in diabetic nephropathy [5].

Angiotensin-converting enzyme inhibitors (ACEIs) and Angiotensin receptor blockers (ARBs) ACE inhibitors and ARBs are well-established treatments for diabetic nephropathy, primarily due to their ability to block the effects of angiotensin II and reduce blood pressure. These medications also have direct anti-inflammatory effects by inhibiting the activation of pro-inflammatory pathways, including the NF-κB pathway. By reducing the production of inflammatory cytokines and preventing endothelial dysfunction, ACEIs and ARBs help slow the progression of kidney damage in diabetic nephropathy.

Glucagon-like peptide-1 (GLP-1) agonists: GLP-1 agonists, which are commonly used in the treatment of type 2 diabetes, have shown promise in reducing inflammation and protecting against diabetic nephropathy. These drugs act by enhancing insulin secretion, improving glucose control, and reducing oxidative stress. Recent studies suggest that GLP-1 agonists can also reduce the expression of pro-inflammatory cytokines and attenuate kidney fibrosis, making them a potential therapeutic option for patients with diabetic nephropathy.

SGLT2 inhibitors: Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a newer class of drugs that have gained attention for their ability to improve glycemic control and protect against kidney damage in diabetic patients. SGLT2 inhibitors reduce hyperglycemia by blocking glucose reabsorption in the kidneys, but they also have beneficial effects on inflammation. Studies have shown that SGLT2 inhibitors can reduce the levels of pro-inflammatory cytokines and mitigate oxidative stress, ultimately protecting against the progression of diabetic nephropathy.

Anti-Inflammatory agents and cytokine inhibitors: Targeting specific pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-6, holds promise for the treatment of diabetic nephropathy. In preclinical models, the use of cytokine inhibitors has been shown to reduce kidney inflammation and fibrosis. Although clinical trials targeting these cytokines are still ongoing, these agents may provide a more direct approach to modulating the inflammatory response in diabetic nephropathy [6].

Conclusion

Microinflammation plays a crucial role in the development and progression of diabetic nephropathy, contributing to kidney injury, fibrosis, and eventual renal failure. By understanding the complex mechanisms that drive inflammation in diabetic kidneys, researchers and clinicians can develop more targeted therapies aimed at reducing inflammation and preserving kidney function. Current treatments, such as ACE inhibitors, ARBs, GLP-1 agonists, and SGLT2 inhibitors, have shown promise in mitigating the inflammatory response and slowing the progression of diabetic nephropathy. As research continues, novel anti-inflammatory agents and cytokine inhibitors may offer additional therapeutic options for managing this devastating complication of diabetes. Ultimately, a combination of pharmacological and lifestyle interventions will be essential for managing microinflammation and improving outcomes for patients with diabetic nephropathy.

Acknowledgement

None

Conflict of Interest

None

References

1. Finianos A, Aragon-Ching JB (2019) Zoledronic acid for the treatment of prostate cancer. Expert Opin Pharmacother 20: 657-666.

   Indexed at, Google Scholar, Crossref

2. Nguyen PL, Alibhai SM, Basaria S, D Amico AV, Kantoff PW, et al. (2015) Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67: 825-836.

   Indexed at, Google Scholar, Crossref

3. Powell IJ (2007) Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol 177: 444-449.

   Indexed at, Google Scholar, Crossref

4. Hsing AW, Yeboah E, Biritwum R, Tettey Y, De Marzo AM, et al. (2014) High prevalence of screen detected prostate cancer in West Africans: implications for racial disparity of prostate cancer. J Urol 192: 730-736.

   Indexed at, Google Scholar, Crossref

5. Huggins C (1963) The hormone-dependent cancers. Jama 186: 481-483.

   Indexed at, Google Scholar, Crossref

6. Semenas J, Allegrucci C, Boorjian AS, Mongan PN, Liao Persson J (2012) Overcoming drug resistance and treating advanced prostate cancer. Current drug targets 13: 1308-1323.

   Indexed at, Google Scholar, Crossref

7. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, et al. (2016) NCCN guidelines insights: prostate cancer early detection, version 2.2016. Natl Compr Canc Netw 14: 509-519.

   Indexed at, Google Scholar, Crossref